US Defense Secretary Pete Hegseth announced on July 15, 2026, that the Department of Defense will require all active-duty and reserve component service members aged 30 and older to undergo annual screening for testosterone deficiency as part of their Periodic Health Assessment.
Younger service members may request the test voluntarily.
Any recommended testosterone replacement therapy will remain entirely optional.
Why is the Pentagon screening for testosterone?
In a video posted on social media under the caption ‘The High-T Department of War,’ Mr. Hegseth described the initiative as a measure to help troops ‘operate at their absolute best’ by addressing natural declines in testosterone levels that occur with age. He emphasized that the program focuses on restoring and optimizing natural capabilities rather than artificial performance enhancement, while supporting overall resilience, longevity, and combat readiness.
A formal memorandum signed the same day directed immediate implementation. By August 15, 2026, relevant policies, including the Periodic Health Assessment instruction, are to be updated.
The Military Departments and Defense Health Agency were tasked with aligning procedures and educating medical personnel and service members. Officials linked the effort in part to lessons from ‘Operator Syndrome,’ a set of health challenges, including low testosterone, observed in special operations forces that the department aims to address more broadly across the force.
Pentagon spokesman Sean Parnell stated that the protocol would establish a comprehensive baseline and enable targeted therapy where appropriate, helping sustain a ‘healthy, capable, and decisively dominant fighting force.’ Mr. Hegseth noted that treatment decisions would rest with the individual service member under medical supervision.
What’s the reaction?
The announcement has drawn mixed reactions from medical experts. Some expressed caution, noting that major medical guidelines generally advise against routine population-wide screening for low testosterone in the absence of symptoms, and pointed to the side effects of therapy (including impacts on fertility), and the applicability of existing research to a young, fit military population.
Others acknowledged possible benefits for service members experiencing genuine deficiencies linked to high operational stress or specific conditions. Details on testing protocols, cost coverage for therapy, and implications for female service members have not been fully elaborated by the department. The policy aligns with broader recent efforts by the Defense Department to emphasize physical standards, fitness, and human performance optimization. Implementation is underway through the Military Health System, with further clinical guidance expected from health affairs officials.